These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36617363)

  • 1. Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review.
    Kouranloo K; Ashley A; Zhao SS; Dey M
    Rheumatol Int; 2023 Jun; 43(6):1023-1032. PubMed ID: 36617363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.
    Kouranloo K; Dey M; Almutawa J; Myall N; Nune A
    Rheumatol Int; 2024 Jul; 44(7):1219-1232. PubMed ID: 38129348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome.
    Borie R; Debray MP; Guedon AF; Mekinian A; Terriou L; Lacombe V; Lazaro E; Meyer A; Mathian A; Ardois S; Vial G; Moulinet T; Terrier B; Jamilloux Y; Heiblig M; Bouaziz JD; Zakine E; Outh R; Groslerons S; Bigot A; Flamarion E; Kostine M; Henneton P; Humbert S; Constantin A; Samson M; Bertrand NM; Biscay P; Dieval C; Lobbes H; Jeannel J; Servettaz A; Adelaide L; Graveleau J; de Sainte-Marie B; Galland J; Guillotin V; Duroyon E; Templé M; Bourguiba R; Georgin Lavialle S; Kosmider O; Audemard-Verger A;
    Chest; 2023 Mar; 163(3):575-585. PubMed ID: 36272567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
    Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
    Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings.
    Hines AS; Mohandesi NA; Lehman JS; Koster MJ; Cantwell HM; Alavi A; Warrington KJ; Mangaonkar AA; Go RS; Patnaik MM; Sartori-Valinotti JC
    Int J Dermatol; 2023 Jul; 62(7):938-945. PubMed ID: 36890121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist.
    Sterling D; Duncan ME; Philippidou M; Salisbury JR; Kulasekararaj AG; Basu TN
    J Am Acad Dermatol; 2023 Dec; 89(6):1209-1214. PubMed ID: 35121074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary manifestations in VEXAS syndrome.
    Casal Moura M; Baqir M; Tandon YK; Samec MJ; Hines AS; Reichard KK; Mangaonkar AA; Go RS; Warrington KJ; Patnaik MM; Koster MJ; Ryu JH
    Respir Med; 2023 Jul; 213():107245. PubMed ID: 37062498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome in the intensive care unit: a case report.
    Belicard F; Belhomme N; Bouzy S; Saillard C; Nedelec F; Mear JB; Ardois S; Pastoret C; Reizine F; Camus C; Painvin B
    J Med Case Rep; 2023 Jul; 17(1):314. PubMed ID: 37480098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary manifestations of VEXAS syndrome with acute interstitial pneumonia and diffuse alveolar hemorrhage: a case report and literature review.
    Puseljic M; Schmid J; Igrec J; Hatzl S; Scholz L; Wölfler A; Fuchsjäger M; Talakic E
    ARP Rheumatol; 2024; 3(2):151-156. PubMed ID: 38956997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment.
    Tozaki N; Tawada C; Niwa H; Mizutani Y; Shu E; Kawase A; Miwa Y; Ohnishi H; Sasai H; Miyako K; Hosokawa J; Kato A; Kobayashi K; Miyazaki T; Shirakami Y; Shimizu M; Iwata H
    Front Med (Lausanne); 2022; 9():1046820. PubMed ID: 36544501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin Manifestations of VEXAS Syndrome and Associated Genotypes.
    Tan IJ; Ferrada MA; Ahmad S; Fike A; Quinn KA; Groarke EM; Beck DB; Allbritton J; Castelo-Soccio L; Young NS; Patel BA; Grayson PC; Cowen EW
    JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38865133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: A Narrative Review.
    Padureanu V; Marinaș CM; Bobirca A; Padureanu R; Patrascu S; Dascalu AM; Bobirca F; Tribus L; Alexandru C; Serboiu C; Dumitrascu C; Musetescu A
    Cureus; 2024 Jan; 16(1):e53041. PubMed ID: 38410307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field.
    Phan L; Hammond D; Wilson NR; Groarke EM; Patnaik MM; Pemmaraju N
    Leuk Lymphoma; 2024 May; ():1-13. PubMed ID: 38770970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular and orbital manifestations in VEXAS syndrome.
    Abumanhal M; Leibovitch I; Zisapel M; Eviatar T; Edel Y; Ben Cnaan R
    Eye (Lond); 2024 Jun; 38(9):1748-1754. PubMed ID: 38548942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
    Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE
    Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEXAS-Syndrome, a newly described autoinflammatory systemic disease with dermatologic manifestations.
    Baur V; Stoevesandt J; Hueber A; Hüffmeier U; Kneitz H; Morbach H; Schultz E; Goebeler M
    J Dtsch Dermatol Ges; 2023 Dec; 21(12):1456-1463. PubMed ID: 37953404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
    Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
    Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic manifestations of VEXAS syndrome.
    Groarke EM; Dulau-Florea AE; Kanthi Y
    Semin Hematol; 2021 Oct; 58(4):230-238. PubMed ID: 34802545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
    Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
    JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEXAS Syndrome: A Novelty in MDS Landscape.
    Templé M; Kosmider O
    Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.